Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
133 studies found for:    "AL amyloidosis"
Show Display Options
RSS Create an RSS feed from your search for:
"AL amyloidosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
2 Recruiting Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bendamustine;   Drug: Dexamethasone
3 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
4 Unknown  High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Device: High Cut-off Hemodialysis;   Drug: Chemotherapy
5 Unknown  Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Intervention: Drug: Pomalidomide and Dexamethasone
6 Recruiting A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide;   Drug: Dexamthasone
7 Unknown  Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
8 Active, not recruiting Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Conditions: Primary Systemic Amyloidosis;   Light Chain Deposition Disease
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
9 Recruiting Allo SCT in Amyloidosis Non-interventional Study
Condition: AL Amyloidosis
Intervention:
10 Completed Radioimmunoimaging of Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
11 Recruiting Pomalidomide, Bortezomib, and Dexamethasone as First-Line Treatment in Treating Patients With Amyloid Light-Chain Amyloidosis or Light Chain Deposition Disease
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone
12 Terminated Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: Primary Systemic Amyloidosis
Interventions: Drug: 4'-iodo-4'-deoxydoxorubicin;   Other: pharmacological study
13 Active, not recruiting Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Condition: Primary Systemic Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
14 Completed
Has Results
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone
15 Active, not recruiting Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
16 Recruiting Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Doxycycline
17 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
18 Completed Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Condition: Primary Systemic Amyloidosis (AL)
Interventions: Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous stem cell transplantation
19 Suspended Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Enbrel
20 Completed
Has Results
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: melphalan;   Drug: dexamethasone;   Drug: bortezomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years